Pyxis Oncology, Inc. Overview
Pro stress-test →Pyxis Oncology is a clinical-stage biotech company developing therapeutics to treat solid tumors, with lead programs including PYX-201 (an antibody-drug conjugate in Phase 1) and PYX-106 (a Siglec-15-targeting immunotherapy also in Phase 1). The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Strategic Profile
Pro stress-test →Pyxis has an in-license agreement with Pfizer to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203. The company is also advancing PYX-107, a CD40 agonist in Phase 2 development for soft tissue sarcomas, esophageal, and pancreatic cancers. The company believes that antibody-drug conjugates and immunotherapies offer unique potential to address difficult-to-treat cancers.
Competitive Landscape
Pro stress-test →Pyxis competes in the immuno-oncology/ADC space with companies including Vistagen Therapeutics, Janux Therapeutics, BioAtla, Werewolf Therapeutics, and TScan Therapeutics. The ADC segment is crowded but Pyxis differentiates through novel mechanism-of-action (three-pronged MOA for MICVO) and the Pfizer partnership, which provides validation and commercialization support versus pure clinical-stage competitors.
Industry Context
Pyxis Oncology, Inc. operates in Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology).
Key facts
Founded: 2018 · Headquarters: Boston, United States · Market cap: $~300M